BTIG analyst Ryan Zimmerman raised the firm’s price target on Abbott to $130 from $125 and keeps a Buy rating on the shares as part of a broader research note titled "Q1 MedTech Quarterly Preview". While dynamics are improving, "nobody is in the clear yet", with more inflation still being present, interest rates remaining elevated, and recessionary risk looming over the global economy, the analyst tells investors in a research note. The firm adds however that procedures and staffing appear to be improving, capital equipment demand remains healthy, and FX has become less of a headwind for most names under coverage, setting up improvement for margins in the second half of the year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott price target lowered to $116 from $123 at Raymond James
- Abbott Laboratories (ABT) Q1 Earnings Cheat Sheet
- Abbott says FDA clears reader for FreeStyle Libre 3 system
- Needham med tech analysts to hold an analyst/industry conference call
- Abbott says no FreeStyle Libre readers being physically recalled